natgillin/translations-raw huggingface dataset:
The pharmaceutical composition for use of any one of claims 1 to 5, wherein a second therapeutic agent is administered to the subject before, after, or concurrent with the pharmaceutical composition, wherein, preferably, the second therapeutic agent is selected from the group consisting of: a TNF inhibitor, an IL-1 inhibitor, an IL-5 inhibitor, an IL-8 inhibitor, an IgE inhibitor, a leukotriene inhibitor, a corticosteroid, a methylxanthine, an NSAID, nedocromil sodium, cromolyn sodium, a long-acting beta2 agonist, an anti-fungal agent, and a combination thereof. 
Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time što se drugo terapijsko sredstvo daje subjektu prije, poslije, ili istodobno s farmaceutskim pripravkom, pri čemu je, poželjno, drugo terapijsko sredstvo odabrano iz skupine koja sadrži: inhibitor TNF, inhibitor IL-1, inhibitor IL-5, inhibitor IL-8, inhibitor IgE, inhibitor leukotriena, kortikosteroid, metilksantin, NSAID, nedokromil natrij, kromolin natrij, dugo djelujući beta2 agonist, antigljivično sredstvo, te njihovu kombinaciju.
The pharmaceutical composition for use of claim 7 or 8, wherein a second therapeutic agent is administered to the subject before, after, or concurrent with the initial dose and/or the secondary dose of the pharmaceutical composition, wherein, preferably, the second therapeutic agent is selected from the group consisting of: a TNF inhibitor, an IL-1 inhibitor, an IL-5 inhibitor, an IL-8 inhibitor, an IgE inhibitor, a leukotriene inhibitor, a corticosteroid, a methylxanthine, an NSAID, nedocromil sodium, cromolyn sodium, a long-acting beta2 agonist, an anti-fungal agent, and a combination thereof. 
Farmaceutski pripravak za uporabu prema zahtjevu 7 ili 8, naznačen time što se drugo terapijsko sredstvo daje subjektu prije, poslije, ili istodobno s početnom dozom i/ili sekundarnom dozom farmaceutskog pripravka, pri čemu je, poželjno, drugo terapijsko sredstvo odabrano iz skupine koja sadrži: inhibitor TNF, inhibitor IL-1, inhibitor IL-5, inhibitor IL-8, inhibitor IgE, inhibitor leukotriena, kortikosteroid, metilksantin, NSAID, nedokromil natrij, kromolin natrij, dugo djelujući beta2 agonist, antigljivično sredstvo, te njihovu kombinaciju.
The pharmaceutical composition for use of any one of claims 7-9, wherein each secondary dose is administered 1 to 8 weeks after the immediately preceding dose, or wherein at least 8 secondary doses of the antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R) are administered to the subject, and wherein each secondary dose is administered 1 week after the immediately preceding dose. 
Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 7-9, naznačen time što se svaka sekundarna doza primjenjuje 1 do 8 tjedana neposredno nakon prethodne doze, ili pri čemu se najmanje 8 sekundarnih doza protutijela ili njegovog ulomka koji veže antigen koji specifično veže interleukin-4 receptor (IL-4R) primjenjuju na subjekta, i pri čemu svaka sekundarna doza se primjenjuje 1 tjedan neposredno nakon prethodne doze.
administering to the patient a defined dose of the antibody or antigen-binding fragment thereof at a defined frequency for an initial treatment period while maintaining the patient's background asthma therapy for the initial treatment period; and 
davanje pacijentu određene doze protutijela ili njegovog ulomka koji veže antigen uz određenu frekvenciju kroz početno razdoblje liječenja uz održavanje pacijentove pozadinske terapije za astmu kroz početno razdoblje liječenja; i
The antibody or antigen-binding fragment thereof for use of claim 12 or 13, wherein the dosage of LABA is eliminated at the end of the initial treatment period, and/or wherein the dosage of LABA and /or ICS is gradually reduced or eliminated over the course of 2 to 8 weeks. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 12 ili 13, naznačen time što se doziranje LABA eliminira na kraju početnog razdoblja liječenja, i/ili pri čemu se doziranje LABA i/ili ICS postupno smanjuje ili eliminira tijekom vremena od 2 do 8 tjedana.
The anti-Factor D antibody or Factor D-binding fragment thereof of claim 1(ii), comprising a light chain variable domain of the amino acid sequence of SEQ ID NO:7, wherein the amino acid at position 104 of SEQ ID NO:7 is a valine. 
Protutijelo protiv čimbenika D, ili njegov fragment koji se veže na čimbenik D, u skladu s patentnim zahtjevom 1(ii), naznačeno time što sadrži aminokiselinski slijed varijabilne domene lakog lanca u SEQ ID NO:7, gdje je aminokiselina na položaju 104 u SEQ ID NO:7 valin.
The anti-Factor D antibody or the Factor D-binding fragment thereof of claim 1(iv), comprising a light chain variable domain of the amino acid sequence: 
Protutijelo protiv čimbenika D, ili njegov fragment koji se veže na čimbenik D, u skladu s patentnim zahtjevom 1(iv), naznačeno time što sadrži aminokiselinski slijed varijabilne domene lakog lanca:
The anti-Factor D antibody or the Factor D-binding fragment thereof of claim 1(iv), 7 or 8, comprising a heavy chain variable domain of the amino acid sequence: 
Protutijelo protiv čimbenika D, ili njegov fragment koji se veže na čimbenik D, u skladu s patentnim zahtjevom 1(iv), 7 ili 8, naznačeno time što sadrži aminokiselinski slijed varijabilne domene teškog lanca:
a light chain variable domain of the amino acid sequence: 
aminokiselinski slijed varijabilne domene lakog lanca:
A composition comprising the anti-Factor D antibody or the Factor D-binding fragment thereof of any one of claims 1 to 11 for use in a method of treating disorders associated with excessive or uncontrolled complement activation. 
Pripravak koji sadrži protutijelo protiv čimbenika D, ili njegov fragment koji se veže na čimbenik D, u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je namijenjen upotrebi u postupku liječenja poremećaja povezanih s prekomjernim ili nekontroliranim aktiviranjem komplementa.
Use of the composition of claim 15 for the preparation of a medicament for treating disorders associated with excessive or uncontrolled complement activation. 
Upotreba pripravka u skladu s patentnim zahtjevom 15, naznačena time što je pripravak namijenjen pripravi medikamenta za liječenje poremećaja povezanih s prekomjernim ili nekontroliranim aktiviranjem komplementa.
an ocular disease such as age-related macular degeneration or diabetic retinopathy; or 
očna bolest, poput staračke degeneracije makule ili dijabetične retinopatije; ili
associated with: cardiopulmonary bypass operations, ischemia-reperfusion following acute myocardial infarction, aneurysm, stroke, hemorrhagic shock, crush injury, multiple organ failure, hypobolemic shock, intestinal ischemia or other events causing ischemia; inflammatory conditions such as severe burns, endotoxemia, septic shock, adult respiratory distress syndrome, hemodialysis; anaphylactic shock, severe asthma, angioedema, Crohn's disease, sickle cell anemia, poststreptococcal glomerulonephritis and pancreatitis; an adverse drug reaction, drug allergy, IL-2 induced vascular leakage syndrome or radiographic contrast media allergy; autoimmune disease such as systemic lupus erythematosus, myasthenia gravis, rheumatoid arthritis, Alzheimer's disease and multiple sclerosis; or transplant rejection. 
povezan s: operacijama postavljanja kardiopulmonalne premosnice, ishemijom uz reperfuziju nakon akutnog infarkta miokarda, aneurizme, inzulta, hemoragijskog šoka, ozljede s nagnječenjem, višeorganske insuficijencije, hipovolemijskog šoka, crijevne ishemije ili drugih pojava koje uzrokuju ishemiju; upalnim stanjima, poput teških opeklina, endotoksemije, septičnog šoka, sindroma dišnog distresa kod odraslih, hemodijalize; anafilaktičkim šokom, teškom astmom, angioedemom, Crohnovom bolešću, anemijom srpastih stanica, poststreptokoknim glomerulonefritisom i pankreatitisom; štetnom reakcijom na lijekove, alergijom na lijekove, sindroma curenja iz žila uzrokovanog s IL-2 ili alergijom na radiografske kontrastne medije; autoimunim bolestima, poput sistemnog eritematoznog lupusa, miastenije gravis, reumatoidnog artritisa, Alzheimerove bolesti i multiple skleroze; ili odbacivanjem presatka.
A compound for use in treating a disease or disorder in a subject, the compound being of Formula (V): or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof; 
Spoj za uporabu u liječenju bolesti ili poremećaja kod subjekta, te spoj ima Formulu (V): ili njegova farmaceutski prihvatljiva sol, ester, solvat ili predlijek;
A compound for use in treating a disease or disorder in a subject, the compound being of Formula (VI): or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof; wherein 
Spoj za uporabu u liječenju bolesti ili poremećaja kod subjekta, te spoj ima Formulu (VI): ili njegova farmaceutski prihvatljiva sol, ester, solvat ili predlijek; naznačen time što
The compound for use according to claim 1, wherein R2 is substituted or unsubstituted fused ring aryl; optionally wherein R2 is fused ring aryl selected from the group consisting of substituted or unsubstituted benzodioxinyl and substituted or unsubstituted naphthyl. 
Spoj za uporabu prema zahtjevu 1, naznačen time što je R2 supstituirani ili nesupstituirani kondenzirani arilni prsten; proizvoljno pri čemu je R2 kondenzirani arilni prsten odabran iz skupine koju čine supstituirani ili nesupstituirani benzodioksinil i supstituirani ili nesupstituirani naftil.
The compound for use according to claim 8, wherein R5 is substituted or unsubstituted fused ring aryl; optionally wherein R5 is fused ring aryl selected from the group consisting of substituted or unsubstituted benzodioxinyl and substituted or unsubstituted naphthyl. 
Spoj za uporabu prema zahtjevu 8, naznačen time što R5 je supstituirani ili nesupstituirani kondenzirani arilni prsten; proizvoljno pri čemu je R5 kondenzirani arilni prsten odabran iz skupine koju čine supstituirani ili nesupstituirani benzodioksinil i supstituirani ili nesupstituirani naftil.
A compound for use according to claim 2, wherein the compound has a structure of formula C: wherein Rx is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, and substituted or unsubstituted heteroaryl; 
Spoj za uporabu prema zahtjevu 2, naznačen time što spoj ima strukturu s formulom C: pri čemu je Rx neovisno odabran iz niza koji čine vodik, supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani heteroalkil, supstituirani ili nesupstituirani cikloalkil, supstituirani ili nesupstituirani heterocikloalkil, supstituirani ili nesupstituirani aril, supstituirani ili nesupstituirani kondenzirani arilni prsten, i supstituirani ili nesupstituirani heteroaril;
The compound for use according to any of claims 1-14, wherein said disease or disorder is a kallikrein-related disorder, wherein said kallikrein-related disorder is one or more selected from the group consisting of a thrombotic disease, a fibrinolytic disease, a type of cancer, an inflammatory condition, a dermatological condition, and an ophthalmic disease. 
Spoj za uporabu prema bilo kojem od zahtjeva 1-14, naznačen time što je navedena bolest ili poremećaj zapravo poremećaj povezan s kalikreinom, pri čemu je navedeni poremećaj koji je povezan s kalikreinom jedan ili više odabranih iz skupine koju čine trombotička bolest, fibrinolitička bolest, vrsta raka, upalno stanje, dermatološko stanje i očna bolest.
The compound for use according to claim 19, wherein said ophthalmic disease is one or more selected from the group consisting of diabetic macular edema, age-related macular degeneration, and diabetic retinopathy; or wherein said type of cancer is one or more selected from the group consisting of cervical-, testicular-, and non-small-cell lung adenocarcinoma; or wherein said inflammatory condition is one or more selected from the group consisting of sepsis, inflammatory bowel disease, systemic inflammatory response syndrome, hereditary angioedema, and rheumatoid arthritis; or wherein said dermatological condition is one or more selected from the group consisting of atopic dermatitis, psoriasis, and Netherton Syndrome. 
Spoj za uporabu prema zahtjevu 19, naznačen time što je navedena očna bolest jedna ili više odabranih iz skupine koju čine dijabetički makularni edem, makularna degeneracija povezana sa starošću i dijabetička retinopatija; ili pri čemu je navedeni tip raka jedan ili više odabranih iz skupine koje čine cervikalni, testikularni i adenokarcinom nemalih stanica pluća; ili pri čemu je navedeno upalno stanje jedno ili više odabrano iz skupine koju čine sepsa, upalna bolest crijeva, sindrom sistemskog upalnog odgovora, hereditarni angioedem, i reumatoidni artritis; ili pri čemu je navedeno dermatološko stanje jedno ili više odabranih iz skupine koju čine atopijski dermatitis, psorijaza i Nethertonov sindrom.
The compound for use according to claim 19, wherein said compound acts by inhibiting kallikrein, preferably wherein said compound acts by inhibiting tissue kallikrein and/or plasma kallikrein. 
Spoj za uporabu prema zahtjevu 19, naznačen time što navedeni spoj djeluje inhibiranjem kalikreina, pri čemu je poželjno da navedeni spoj djeluje inhibiranjem kalikreina u tkivu i/ili kalikreina u plazmi.
The compound for use according to claim 20, wherein said kallikrein-related disorder is an ophthalmic disease, and wherein said compound or pharmaceutical composition is administered orally, in the form of an ophthalmic composition applied topically to the eye or via intravitreal injection, preferably wherein the ophthalmic composition is in the form of eye drops. 
Spoj za uporabu prema zahtjevu 20, naznačen time što je navedeni poremećaj povezan s kalikreinom očna bolest, i pri čemu se navedeni spoj ili farmaceutski pripravak primjenjuje oralno, u obliku oftalmičkog pripravka primijenjenog topikalno u oko ili putem intravitrealne injekcije, pri čemu je poželjno da je oftalmički pripravak u obliku kapi za oči.
C6-10 aryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, cyano, halo, hydroxy, amino, trifluoromethyl, and trifluoromethoxy; and 
-10 aril po izboru supstituiran s 1 do 5 supstituenata koji su neovisno odabrani iz skupine koju čine C1-4 alkil, C1-4 alkoksi, cijano, halo, hidroksi, amino, trifluorometil, i trifluorometoksi; i
C1-10 heteroaryl optionally substituted with 1 to 3 substituents on carbon independently selected from the group consisting of amino, C1-8 alkylamino, C1-9 amide, C1-4 alkyl, C1-4 alkoxy, cyano, halo, hydroxyl, oxo, trifluoromethyl, and trifluoromethoxy, and optionally substituted on a ring nitrogen with a C1-4 alkyl; 
-10 heteroaril po izboru supstituiran s 1 do 3 supstituenata na ugljiku koji su neovisno odabrani iz skupine koju čine amino, C1-8 alkilamino, C1-9 amid, C1-4 alkil, C1-4 alkoksi, cijano, halo, hidroksil, okso, trifluorometil, i trifluorometoksi, i po izboru supstituiran na dušiku u prstenu s C1-4 alkilom;
is selected from the group consisting of C1-6 alkyl and C3-8 cycloalkyl. 
je odabran iz skupine koju čine C1-6 alkil i C3-8cikloalkil.
C1-6 alkyl optionally substituted with 1 to 7 substituents independently selected from the group consisting of: C1-4 alkoxy; C1-9 amide; amino; C1-8 alkylamino; C1-5 oxycarbonyl; cyano; C3-8 cycloalkyl; halo; hydroxy; and C3-6 heterocyclyl optionally substituted on any ring nitrogen by C1-4 alkyl; C1-10 heteroaryl; and phenyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, C1-9 amide, amino, C1-8 alkylamino, C1-5 oxycarbonyl, cyano, halo, hydroxyl, nitro, C1-8 sulfonyl, and trifluoromethyl; 
-6 alkil po izboru supstituiran s 1 do 7 supstituenata koji su neovisno odabrani iz skupine koju čine: C1-4 alkoksi; C1-9 amid; amino; C1-8 alkilamino; C1-5 oksikarbonil; cijano; C3-8 cikloalkil; halo; hidroksi; i C3-6 heterociklil po izboru supstituiran na bilo kojem dušiku u prstenu C1-4 alkil; C1-10 heteroaril; i fenil po izboru supstituiran s 1 do 5 supstituenata koji su neovisno odabrani iz skupine koju čine C1-4 alkil, C1-4 alkoksi, C1-9 amid, amino, C1-8 alkilamino, C1-5 oksikarbonil, cijano, halo, hidroksil, nitro, C1-8 sulfonil, i trifluorometil;
C6-10 aryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, cyano, halo, hydroxy, amino, trifluoromethyl, and trifluoromethoxy; 
-10 aril po izboru supstituiran s 1 do 5 supstituenata koji su neovisno odabrani iz skupine koju čine C1-4 alkil, C1-4 alkoksi, cijano, halo, hidroksi, amino, trifluorometil, i trifluorometoksi;
is selected from the group consisting of CH2 and CHR4 and X4 is NR8; or 
je odabran iz skupine koju čine CH2 i CHR4 i X4is NR8; ili
is NR8 and X4 is selected from the group consisting of CH2 and CHR4; 
je NR8 i X4 je odabran iz skupine koju čine CH2i CHR4;
is selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, and phenyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, C1-9 amide, amino, C1-8 alkylamino, C1-5 oxycarbonyl, cyano, halo, hydroxyl, nitro, C1-8 sulfonyl, and trifluoromethyl; 
je odabran iz skupine koju čine C1-6 alkil, C3-8cikloalkil, i fenil po izboru supstituiran s 1 do 5 supstituenata koji su neovisno odabrani iz skupine koju čine C1-4 alkil, C1-4 alkoksi, C1-9 amid, amino, C1-8 alkilamino, C1-5oksikarbonil, cijano, halo, hidroksil, nitro, C1-8 sulfonil, i trifluorometil;
is selected from the group consisting of hydrogen, C1-6 alkyl and C3-8 cycloalkyl; or 
je odabran iz skupine koju čine vodik, C1-6 alkil i C3-8 cikloalkil; ili
and C1-4 alkoxy; and wherein the 4 to 7 membered saturated ring is substituted on any additional ring nitrogen by a substituent selected from the group consisting of: hydrogen, C3-8 cycloalkyl, and C1-6 alkyl optionally substituted with 1 to 7 substituents independently selected from the group consisting of: C1-4 alkoxy; C1-9 amide; amino; C1-8 alkylamino; C1-5 oxycarbonyl; cyano; C3-8 cycloalkyl; halo; hydroxy; and C3-6 heterocyclyl optionally substituted on any ring nitrogen by C1-4 alkyl; C1-10 heteroaryl; and phenyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, C1-9 amide, amino, C1-8 alkylamino, C1-5 oxycarbonyl, cyano, halo, hydroxyl, nitro, C1-8 sulfonyl, and trifluoromethyl; and 
i C1-4 alkoksi; i pri čemu 4 do 7 člani zasićeni prsten je supstituiran na bilo kojem dodatnom dušiku u prstenu sa supstituentom odabranim iz skupine koju čine: vodik, C3-8 cikloalkil, i C1-6 alkil po izboru supstituiran s 1 do 7 supstituenata koji su neovisno odabrani iz skupine koju čine: C1-4 alkoksi; C1-9 amid; amino; C1-8alkilamino; C1-5 oksikarbonil; cijano; C3-8 cikloalkil; halo; hidroksi; i C3-6 heterociklil po izboru supstituiran na bilo kojem dušiku u prstenu C1-4 alkil; C1-10 heteroaril; i fenil po izboru supstituiran s 1 do 5 supstituenata koji su neovisno odabrani iz skupine koju čine C1-4 alkil, C1-4 alkoksi, C1-9 amid, amino, C1-8 alkilamino, C1-5 oksikarbonil, cijano, halo, hidroksil, nitro, C1-8 sulfonil, i trifluorometil; i
A compound or pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 13, for use in the treatment of a disorder selected from Parkinson's disease, levodopa-induced dyskinesias, Huntington's disease, drug addiction, eating disorders, cognitive disorders, schizophrenia, bipolar disorders, and depression. 
Spoj ili njegova farmaceutski prihvatljiva sol kako je definirano u bilo kojem od zahtjeva 1 do 13, naznačen time što se koristi za liječenje poremećaja odabranih od Parkinsonove bolesti, diskinezija izazvanih levodopom, Huntingtonove bolesti, ovisnosti o drogama, poremećaja prehrane, kognitivnih poremećaja, shizofrenije, bipolarnih poremećaja, i depresije.
determining whether to apply the sample adaptive offset filter operation across the at least one slice boundary according to the second flag. 
u odnosu na barem jedan odsječak, dobivanje drugog pokazatelja da se uzorak prilagodljivog offset postupka treba primijeniti preko granice odsječka;
an X-ray powder diffraction pattern using CuKa radiation having an intense peak at diffraction angle 2-theta of 5.2° in combination with one or more intense peaks selected from the group consisting of 7.8°, 8.0°, and 10.7° (± 0.2° respectively); and 
uzorak difrakcije rendgenskih zraka na prahu uz upotrebu zračenja CuKa s intenzivnim maksimumom kod kuta difrakcije 2θ od 5,2°, u kombinaciji s jednim ili više intenzivnih maksimuma, koje se bira iz skupine koju čine 7,8°, 8,0°, te 10,7° (± 0,2° svaki); i
wherein the term intense peak means a peak having an intensity that is at least 5% that of the most intense peak in the relevant spectrum or powder pattern. 
gdje termin intenzivni maksimum znači maksimum s intenzitetom koji je najmanje 5% od najintenzivnijeg maksimuma u relevantnom spektru ili uzorku na prahu.
A pharmaceutical composition comprising a compound according to any one of claims 1 to 4 with one or more pharmaceutically acceptable carriers, diluents, or excipients. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, uz jednu ili više farmaceutski prihvatljivih podloga, razrjeđivača ili pomoćnih tvari.
A substrate according to claim 4 comprising one or more formulations of the calcium carbonate composition, said formulation selected from the group consisting of a coating composition, filler, surface filling, and a calcium carbonate slurry or mixtures thereof. 
Podloga prema zahtjevu 4 naznačena time što sadrži jednu ili više formulacija pripravka kalcijevog karbonata, navedena formulacija je odabrana iz skupine koja sadrži pripravak za oblaganje, punilo, površinsko punjenje, te suspenziju kalcijevog karbonata ili njihove smjese.
A method for producing a calcium carbonate particle fine fraction from a feed material, the calcium carbonate particle fine fraction, when in a densely compacted bed form, having a monomodal pore diameter distribution and a volume defined median pore diameter from 0.01 to 0.04 micrometre, an intruded total specific void volume of 0.1-0.3 cm3/g, and a volume defined pore size polydispersity expressed as full width at half maximum in the range of 0.01 to 0.03 micrometre, wherein the densely compacted bed is formed in a wet tablet press apparatus from a water slurry of the calcium carbonate particles by applying a constant pressure of 15 bars to the slurry until the water is released by filtration through a 0.025 micrometer filter membrane, and the tablets formed are dried at 60 °C for 24 hours, and wherein the volume defined median pore diameter and the intruded total specific void volume of calcium carbonate particles, when in a densly compacted form, are characterized by mercury porosimetry: 
Postupak za proizvodnju fine frakcije čestica kalcijevog karbonata iz materijala za punjenje, fina frakcija čestica kalcijevog karbonata, kada su u gusto zbijenom sloju, ima monomodalnu razdiobu promjera pora i volumenski definirani srednji promjer pora od 0,01 do 0,04 mikrometara, intrudirani ukupni specifični prazni volumen od 0,1-0,3 cm3/g, i volumenski definiranu polidisperzivnost veličine pora izraženu kao punu širinu pri polovini maksimuma u rasponu od 0,01 do 0,03 mikrometara, pri čemu je gusto zbijeni sloj oblikovan u uređaju za prešanje vlažnih tableta iz vodene suspenzije čestica kalcijevog karbonata primjenom konstantnog tlaka od 15 bara na suspenziju sve dok se voda ne oslobodi filtriranjem kroz 0,025 mikrometarsku filtarsku membranu, a nastale tablete se suše na 60 °C tijekom 24 sata, te pri čemu je volumenski definirani srednji promjer pora i intrudirani ukupni specifični prazni volumen čestica kalcijevog karbonata, kada su u gusto zbijenom obliku, naznačen time što ima živinu porozimetriju: